No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

NGMedical GmbH Announces First Case of Its BEE PLIF in the USA

Editor: What To Know

  • The first operation with the BEE® PLIF cage in this important market is a great milestone in our international commercialization.
  • Tuttle had a discerning appreciation for the BEE® PLIF’s evolutionary design, and was anxious for BEE® as a surgical option.
  •  This promises to be a year of rapid growth as we introduce the inimitable BEE® platform of interbody implants across the country.

NGMedical, a German medical device manufacturer exclusively focused on creating innovative technologies for spinal applications announces the first USA implantation of its purely additively manufactured titanium BEE® PLIF.

The case was performed on February 18th, 2022 by Jonathan A. Tuttle, MD at University Hospital in Augusta, GA.

“The BEE® PLIF implant system represents a refinement of details that matter.  The instruments are elegant and intuitive, and the implant is refined in structure and anatomical design.  I’m pleased to incorporate BEE® PLIF into my armamentarium of surgical solutions for my patients,” said Dr. Tuttle.

Mitch White, President of NGMedical, Inc. added, “I’m excited and honored Dr. Tuttle was the first US surgeon to implant BEE® PLIF, but I’m not surprised.  Dr. Tuttle had a discerning appreciation for the BEE® PLIF’s evolutionary design, and was anxious for BEE® as a surgical option. This promises to be a year of rapid growth as we introduce the inimitable BEE® platform of interbody implants across the country.”

“This successful market launch in the USA is an important step for NGMedical. The first operation with the BEE® PLIF cage in this important market is a great milestone in our international commercialization. We look forward to expanding our portfolio and footprint in the USA.” says Peter Weiland, CEO of NGMedical.

NG Medical notes the BEE® PLIF cage is another significant innovation from the team who invented the first line of additively manufactured interbody devices. The purposefully designed honeycomb endplate design reduces the risk of subsidence, while allowing fusion. The honeycomb structure allows for bony ingrowth while offering a very large graft space. Smooth lateral surfaces facilitate insert and rotate technique. BEE® PLIF is offered in a wide range of sizes up to 18° lordosis.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy